
invention addresses one or more of these needs by providing alternative compounds and treatment methods, which may be suitable for the treatment cardiovascular diseases.

~~The present invention~~In an aspect, there is provide~~s~~ a compound ~~according to~~of the Formula I



I

~~Where~~ wherein R is H or $-CH_3$ or a pharmaceutically acceptable salt thereof.

In one form, the present ~~invention~~ disclosure provides a compound of Formula I wherein R is H or a pharmaceutically acceptable salt thereof.

In another form, the present ~~invention~~ disclosure provides a compound of Formula I wherein R is $-CH_3$ or a pharmaceutically acceptable salt thereof.

The present ~~invention~~ disclosure provides a method for treating a patient in need of treatment for cardiovascular diseases. The method comprises administering to the patient a compound according to Formula I, or a pharmaceutically acceptable salt thereof. In one embodiment the administered compound, or pharmaceutically acceptable salt thereof, is a compound of Formula I wherein R is H. In another embodiment the administered compound, or pharmaceutically salt thereof, is a compound of Formula I wherein R is $-CH_3$.

In another form, the present ~~invention~~ disclosure provides a method for treating a patient in need of treatment for dyslipidemia. The method comprises administering to the patient a compound of the present ~~invention~~ disclosure according to Formula I, or a pharmaceutically acceptable salt thereof. In one embodiment the administered compound, or pharmaceutically acceptable salt thereof, is a compound of Formula I wherein R is H. In another embodiment the administered compound or pharmaceutically salt thereof is a compound of Formula I wherein R is $-CH_3$.

In yet another form, the present disclosure~~invention~~ provides a method for treating a patient in need of treatment for atherosclerosis. The method comprises administering to the patient a compound according to Formula I, or a pharmaceutically acceptable salt thereof. In one embodiment the administered compound, or pharmaceutically acceptable salt thereof, is a compound of Formula I wherein R is H. In another embodiment the

administered compound, or pharmaceutically salt thereof, is a compound of Formula I wherein R is $-CH_3$.

In one form, the present ~~invention~~ disclosure provides a method for treating a patient in need of treatment for hypertriglyceridemia. The method comprises administering to the patient a compound according to Formula I, or a pharmaceutically acceptable salt thereof. In one embodiment the administered compound, or pharmaceutically acceptable salt thereof, is a compound of Formula I wherein R is H. In another embodiment the administered compound, or pharmaceutically salt thereof, is a compound of Formula 1 wherein R is $-CH_3$.

The present ~~invention~~ disclosure provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier or excipient.

In another aspect, there is provided a pharmaceutical composition comprising a compound as defined above, or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier or excipient.

Such pharmaceutical compositions and processes for preparing the compositions are known in the art. (See e.g., Remington; The Science and Practice of Pharmacy, D.B. Troy, Editor, 21st Edition, Lippinncott, Williams & Wilkins, 2006).

The present ~~invention~~ disclosure provides a method for treating a patient in need of treatment for cardiovascular disease, dyslipidemia, atherosclerosis, or hypertriglyceridemia. The method comprises administering to the patient a pharmaceutical composition comprising a compound according to Formula I, or a pharmaceutically acceptable salt thereof. In one embodiment the administered pharmaceutical composition comprises of Formula I wherein R is H or pharmaceutically acceptable salt thereof. In another embodiment the administered compound or pharmaceutical composition comprises a compound of Formula I wherein R is $-CH_3$, or pharmaceutically acceptable salt thereof.

~~The present invention~~In another aspect, there is provide~~d~~s a compound ~~of the invention~~as defined above for use in therapy. In one embodiment the compound or pharmaceutically acceptable salt thereof is a compound of Formula I wherein R is H. In another embodiment the compound or pharmaceutically salt thereof is a compound of Formula I wherein R is $-CH_3$.

In one embodiment the therapy comprises the use of a compound ~~of the invention~~ as defined above for the treatment of cardiovascular disease. The compound or pharmaceutically acceptable salt thereof is a compound of Formula I wherein R is H. Alternatively, the compound or pharmaceutically salt thereof is a compound of Formula I wherein R is $-CH_3$.

In one embodiment the therapy comprises the use of a compound ~~of the invention~~as defined above for the treatment of dyslipidemia. The compound or pharmaceutically acceptable salt thereof is a compound of Formula I wherein R is H. Alternatively, the compound or pharmaceutically salt thereof is a compound of Formula I wherein R is $-CH_3$.


In another embodiment, the therapy comprises the use of a compound ~~of the invention~~as defined above for the treatment of atherosclerosis. The compound or pharmaceutically acceptable salt thereof is a compound of Formula I wherein R is H. Alternatively, the compound or pharmaceutically salt thereof is a compound of Formula I wherein R is $-CH_3$.

In another embodiment, the therapy comprises the use of a compound ~~of the invention~~as defined above for the treatment of hypertriglyceridemia. The compound or pharmaceutically acceptable salt thereof is a compound of Formula I wherein R is H. Alternatively, the compound or pharmaceutically salt thereof is a compound of Formula I wherein R is $-CH_3$.

The present ~~invention~~ disclosure also includes the use of a compound according to Formula I in the manufacture of a medicament to treat one or more of: hypertriglyceridemia, cardiovascular disease, dyslipidemia, and atherosclerosis.


In another aspect, there is provided the use of a compound as defined above in the manufacture of a medicament to treat hypertriglyceridemia, cardiovascular disease, dyslipidemia or atherosclerosis. In one embodiment the compound or pharmaceutically acceptable salt thereof is a compound of Formula I wherein R is H. In another embodiment the compound or pharmaceutically salt thereof is a compound of Formula I wherein R is $-CH_3$.

The present ~~invention~~ disclosure provides a process for the preparation of a compound of Formula 2 below:




2

wherein R is H or $-CH_3$ and R1 is a protecting group. The method comprises reacting a compound of Formula 3




3

with a compound of Formula 4 below:



4.

In another aspect, there is provided a process for the preparation of a compound of the Formula:




2

wherein R is H or $-CH_3$, and


R1 is H or a nitrogen protecting group, said method comprising:

reacting a compound of Formula 3



3

with a compound of Formula 4 below:




4.

The preparation can further comprise the step of removing the protecting group, R1, of Formula 2 to provide the compound of Formula I.

Examples of various amino protecting functionalities include: carbamates such as C_{1-5} alkyl carbamate, C_{3-6} cycloalkyl carbamate, preferably a t-butyl carbamate, (BOC) or benzyl carbamate (CBZ); amides such as C_{1-3} alkylamide C_{1-3} haloalkylamide, formamide or acetamide chloroacetamide, trifluoridoacetamide; and benzyl amines. Further examples of amino protecting functionalities, methods of preparing the protected amino substituents, and methods for deprotecting the amino substituents can be found in "Protecting Groups in Organic Synthesis", 3rd Ed. Greene, T.W., Wuts, P.G.M., Eds., John Wiley and Sons, New York, 1999. It will be recognized by those skilled in the art that in addition to the protected amino substituent other functional groups that can be readily converted to the amino group can be used. Such functional groups, preparations, and transformations of these groups can be found in "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" by Larock. R.C, Wiley VCH, 1999 and in "March's Advanced Organic Chemistry, Reactions, Mechanisms and Structure" Smith, M.B., and March, J., Wiley-Interscience, 6th Ed. 2007.


The term "pharmaceutically-acceptable salt" as used herein refers a salt of a compound of the invention considered to be acceptable for clinical and/or veterinary use. Pharmaceutically acceptable salts and common methodology for preparing them are well known in the art. *See, e.g.*, P. Stahl, *et al.*, Handbook of Pharmaceutical Salts: Properties, Selection and Use, (VCHA/Wiley-VCH, 2002); S.M. Berge, *et al.*, "Pharmaceutical Salts," *Journal of Pharmaceutical Sciences*, Vol. 66, No. 1, January 1977.

As used herein, the term "effective amount" of a compound of Formula I refers to an amount, that is a dosage, which is effective in treating a disorder, such as cardiovascular



3

with a compound of Formula 4 below:



4.

~~6. The process of claim 5 wherein where R1 is a protecting group and the process further comprises removing the protecting group.~~

~~7~~6. A compound according to any one of claims 1 to 3 for use in therapy.

~~8~~7. A compound according to claim 7 wherein said therapy is the treatment of cardiovascular disease, dyslipidemia, atherosclerosis or hypertriglyceridemia.

~~9. A compound according to claim 7 wherein said therapy is the treatment of dyslipidemia.~~

~~10. A compound according to claim 7 wherein said therapy is the treatment of atherosclerosis.~~

~~11. A compound according to claim 7 wherein said therapy is the treatment of hypertriglyceridemia.~~

~~128~~. Use of a compound according to any one of claims 1 to 3 in the manufacture of a medicament to treat hypertriglyceridemia, cardiovascular disease, dyslipidemia, or atherosclerosis.